ARS Pharma rises after Japan nod for neffy nasal spray for allergy
Source: SeekingAlpha
2025-09-19 08:34:22 ET
More on ARS Pharmaceuticals, Alfresa Holdings Corporation
- ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript
- ARS Pharmaceuticals: High Risk High Reward Rollout Of No Needle Epinephrine
- ARS Pharmaceuticals: 'Betting On The Come'
- ARS Pharma drops 9% as Lupin files application for generic neffy
- ARS Pharmaceuticals signals continued neffy momentum with 180% prescription surge and global expansion targets
Read the full article on Seeking Alpha
For further details see:
ARS Pharma rises after Japan nod for neffy nasal spray for allergy
Alfresa Holdings Corp Tokyo
NASDAQ: ARHCF
ARHCF Trading
100.0% G/L:
$11.87 Last:
871 Volume:
$0 Open:
